ClinicalTrials.gg
CompletedNCT02729038Updated Jul 21, 2020Results posted

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

A Phase 1 interventional study of Gepotidacin in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-21.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.

Enrollment
7th of 11
32 · median 34
Started
2016
with 1 other
Phase 1
9 of 11
1 open now
Registered
4th of 11
by date
Lead sponsor
10 of 11
GlaxoSmithKline

Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 1, and was the 4th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About gepotidacin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing gepotidacin in Bacterial Infections, or all of them as a file.
02

Study summary

This study will be conducted to determine if altered renal function affects the plasma pharmacokinetics of gepotidacin, which will inform if dosing recommendations based upon renal impairment are required. The objective of this study is to compare the pharmacokinetics of gepotidacin administered as a 750 milligram (mg) intravenous (IV) dose in normal healthy subjects compared with subjects with mild, moderate, and severe renal impairment, and with subjects with end stage renal disease (ESRD). This is a Phase I, nonrandomized, open-label, parallel-group, multi-center, multi-part study. In Part 1, up to 16 subjects with normal renal function will be matched to approximately 8 subjects with moderate renal impairment, and approximately 8 subjects with severe renal impairment and/or subjects with ESRD not on hemodialysis for a total of approximately 32 subjects. In Part 2 (optional), approximately 4 to 8 subjects with normal renal function (if enrolled), approximately 4 to 8 subjects with mild renal impairment, and approximately 4 to 8 subjects with ESRD on hemodialysis will be enrolled for a total of approximately 12 to 24 subjects. The duration from Screening to the Follow-up Visit will be approximately 44 days for Part 1 and approximately 50 days for Part 2.

03

Conditions studied

  • Infections, Bacterial

Keywords

  • Normal Renal Function
  • end stage renal disease (ESRD)
  • Pharmacokinetics
  • Gepotidacin
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Male or female subject between 18 and 80 years of age, inclusive.
  • Healthy subject must be in clinically stable health as determined by the investigator based on medical history, clinical laboratory results (serum chemistry, hematology, urinalysis, and serology), vital sign measurements, 12 lead results, and physical examination findings. Subject with renal impairment must have clinical laboratory values consistent with their disease and are approved by the investigator.
  • Subject with renal impairment (mild, moderate, severe, or subjects with ESRD) may be taking medications, which in the opinion of the investigator, are believed to be therapeutic but do not affect study drug absorption, distribution, metabolism, or excretion. These medications must be stable doses taken for at least 7 days before the first dose of study drug.
  • Subject with normal renal function or renal impairment (estimated [eGFR] corresponding to the calculated eGFR [the estimated eGFR may be rounded to the nearest integer]) at Screening.
  • Subjects with ESRD on hemodialysis should be on hemodialysis for at least 3 months before Screening and is able to tolerate a hemodialysis treatment lasting 3 to 4 hours with blood flow rates of >200 milliliter (mL)/minute (min).
  • (ALT) and \<1.5 × (ULN; isolated bilirubin >1.5 × ULN is acceptable, if bilirubin is fractionated and direct bilirubin \<35%).
  • Body weight >=50 kilograms (kg) and (BMI) within the range 18.5 and 40 kg/square meter (m\^2), inclusive.
  • Male or Female. A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin test), not lactating, and at least one of the following conditions applies:

Nonreproductive potential defined as:

  • Premenopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, or Documented bilateral oophorectomy
  • defined as 12 months of continuous spontaneous amenorrhea (in questionable cases a blood sample will be obtained to test for simultaneous follicle-stimulating hormone) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.

and agrees to follow 1 of the options listed in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential requirements from 30 days prior to the first dose until completion of the Follow-up Visit.

For subjects with indeterminate pregnancy test results or a persistently low human chorionic gonadotropin results, nonpregnancy status must be documented by other means (subjects with ESRD only).

  • Capable of giving signed as described in protocol, which includes compliance with the requirements and restrictions listed in the consent form and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has a abnormality in past medical history or at the Screening physical examination (excluding renal insufficiency and other related stable medical conditions within the renally impaired population of subjects [e.g., hypertension, diabetes, or anemia, which should be stable for at least 3 months before the first dose of study drug]) that in the investigator's opinion may place the subject at risk or interfere with outcome variables of the study. This includes, but is not limited to, history or current cardiac, hepatic, neurologic, gastrointestinal (GI), respiratory, hematologic, or immunologic disease.

Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk, in the opinion of the investigator.

  • Subject has a functioning renal transplant.
  • Subject with renal impairment has a systolic blood pressure outside the range of 90 to 200 millimeter of mercury (mm Hg), a diastolic blood pressure outside the range of 45 to 110 mm Hg, or a heart rate outside the range of 40 to 120 beats per minute (bpm).
  • Subject with renal impairment has a value \<9 grams (g)/decilitre (dL).
  • Female subject has a positive pregnancy test result or is lactating at Screening or upon admission to the clinic.
  • Use of a systemic antibiotic within 30 days of Screening
  • Within 2 months before Screening, either a confirmed history of Clostridium difficile diarrhoea infection or a past positive Clostridium difficile toxin test.
  • Subject has a history of drug and/or alcohol abuse within 6 months before Screening, as determined by the investigator, or subject has a positive drug screen at Screening or upon admission to the clinic. For subjects with renal impairment, a positive drug screen result related to the use of prescription medications is allowed per investigator review and approval, and tetrahydrocannabinol use is allowed per investigator review and approval.
  • History of sensitivity to any of the study drugs, components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) medical monitor, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinic uses heparin to maintain IV cannula patency).
  • Subject has used medications known to affect the elimination of serum creatinine (e.g., trimethoprim or cimetidine) or competitors of renal tubular secretion (e.g., probenecid) within 30 days before dosing.
  • Subjects cannot use any over-the-counter, or prescription medication (except for hormonal and/or acetaminophen), vitamin supplement, or herbal medication within 7 days (or 5 half-lives, whichever is longer) before dosing and during the study within 7 days before dosing and during the study.
  • Subjects with normal renal function have a presence of surface antigen or positive antibody test result at Screening or within 3 months prior to first dose of study treatment. A subject with renal impairment with stable hepatitis C who has normal liver function test results is allowed with investigator approval.
  • A positive test for antibody.
  • Subject has clinically significant abnormal findings in serum chemistry, hematology, or urinalysis results obtained at Screening or Day -1 (and Day 7 for Group F only), other than those associated with underlying renal conditions or other stable medical conditions consistent with the disease process.
  • Subject with normal renal function has a baseline interval using the Fridericia formula (QTcF) of >450 milliseconds (msec) and subject with renal impairment has a baseline QTcF of >480 msec.
  • Donation of blood in excess of 500 mL within 12 weeks prior to dosing or participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Previous exposure to gepotidacin within 12 months prior to the first dosing day.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Subject is unable to comply with all study procedures, in the opinion of the investigator.
  • The subject should not participate in the study, in the opinion of the investigator or Sponsor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part 1: Subjects with normal renal function (Group A)

    Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.

    Drug: Gepotidacin

  • Experimental
    Part 1: subjects with moderate renal impairment (Group B)

    Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.

    Drug: Gepotidacin

  • Experimental
    Part 1: subjects with severe renal impairment (Group C)

    Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.

    Drug: Gepotidacin

  • Experimental
    Part 2: subjects with normal renal function (Group D)

    Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.

    Drug: Gepotidacin

  • Experimental
    Part 2: subjects with mild renal impairment (Group E)

    Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.

    Drug: Gepotidacin

  • Experimental
    Part 2: subjects with ESRD on hemodialysis (Group F)

    Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).

    Drug: Gepotidacin

Interventions

  • Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1

    AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity . Blood samples were collected at the indicated time-points, during the study. The Pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. The PK Population consisted of all participant's, who received at least 1 dose of gepotidacin and had evaluable PK data.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  2. AUC (0-inf) of Gepotidacin for Part 2

    AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for gepotidacin. Blood samples were collected at the indicated time-points, during the study.

    Time frame: Pre-dose, 0.25 hours, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  3. Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1

    Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  4. Cmax of Gepotidacin for Part 2

    Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both.

  5. Total Amount Excreted in Urine (Ae Total), Part 1

    Urine samples from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. No formal statistical analysis of group comparison was planned for urine PK parameters.

    Time frame: Pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period

  6. Ae Total of Gepotidacin for Part 2

    Urine samples, from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. Urine samples were collected at pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.

    Time frame: Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2

  7. Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1

    The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100.

    Time frame: At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period

  8. fe% of Gepotidacin for Part 2

    The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100. No formal statistical analysis of group comparison was planned for urine PK parameters. Only those participants available at the specified time points were analyzed.

    Time frame: At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods

  9. Renal Clearance (CLr) of Gepotidacin for Part 1

    Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). The renal clearance was calculated by Ae total divided by AUC from hour 0 to the last measurable plasma concentration AUC (0-t). Urine samples were collected at pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. No formal statistical analysis of group comparison was planned for urine PK parameters.

    Time frame: At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period

  10. CLr of Gepotidacin for Part 2

    Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). Urine samples were collected at pre-dose (0.0), 0 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.

    Time frame: At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods

  11. AUC (t0-t1) of Gepotidacin for Part 2

    Partial area under the curve estimated from predialyzer samples collected from start of dialysis (t0) to end of dialysis (t1). Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm..

    Time frame: Dialysate fluid were to be collected on Day 1 after dosing (Period 1 only) at pre-dose from 0 to 4 hours

  12. Dialysis Clearance (CLD) of Gepotidacin for Part 2

    CLD measured the dialysis clearance of gepotidacin over the specified duration in the study and indicates how quickly gepotidacin is cleared out from blood or plasma. Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm.

    Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1

  13. Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2

    Dialysate samples were collected at specified time points in the study. Frem is defined as the fraction (dose in percentage) removed by the process of hemodialysis from 0 to 4 hours after the start of hemodialysis (or to the end of dialysis if less than 4 hours)

    Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1

Secondary outcomes

  1. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Readings for Part 1

    Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific timepoints during the study. No formal analysis of group comparison was planned for dialysate PK parameters

    Time frame: Up to 16 Days

  2. Number of Participants With Abnormal 12-lead ECG Readings for Part 2

    Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific time points during the study. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). NA indicates data was not available

    Time frame: Up to 23 Days

  3. Change From Baseline in Vitals- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure, Part 1

    Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Baseline was defined as the latest pre-dose assessment. Change from Baseline, was defined as post Baseline values minus the values at Baseline.

    Time frame: Baseline and up to 16 Days

  4. Change From Baseline in Vitals- SBP and DBP, Part 2

    Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to 23 Days

  5. Change From Baseline in Vitals- Pulse Rate, Part 1

    Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment

    Time frame: Baseline and up to 16 Days

  6. Change From Baseline in Vitals- Pulse Rate, Part 2

    Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and Up to 23 Days

  7. Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) for Part 1

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: Up to 16 Days

  8. Number of Participants With Any AEs and Any SAEs for Part 2

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: Up to 23 Days

  9. Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 1

    The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.

    Time frame: Up to 17 Days

  10. Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 2

    The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.

    Time frame: Up to 24 Days

  11. Number of Participants With Abnormal Physical Examination Results for Part 1

    Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.

    Time frame: Up to 16 Days

  12. Number of Participants With Abnormal Physical Examination Results for Part 2

    Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.

    Time frame: Up to 23 Days

  13. AUC (0-t) of Gepotidacin for Part 1

    Blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  14. AUC (0-t) of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  15. Systemic Clearance (CL) of Gepotidacin for Part 1

    Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).

    Time frame: At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose during the single treatment period.

  16. CL of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).

    Time frame: At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose in each of the two treatment periods

  17. Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1

    Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  18. Lambda_z of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both

  19. Terminal Phase Half-life (t1/2) of Gepotidacin for Part 1

    Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  20. t1/2 of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  21. Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1

    Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  22. Tmax of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  23. Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1

    Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  24. Vss of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  25. Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1

    Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.

  26. Vz of Gepotidacin for Part 2

    Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.

    Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.

  27. Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Normal

    Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function.

    Time frame: At Pre-dose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours

  28. Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Moderate and Severe

    Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: at pre-dose (0.0), 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 36, and 36 to 48 hours post-dose during the single treatment period

  29. Ae(t1-t2) of Gepotidacin for Part 2

    Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function. NA indicates data is not available due to insufficient participants.Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2

  30. Total Amount of Unchanged Amount of Drug Removed by Hemodialysis (Arem) From Time 0 to 1 Hour After the Start of Hemodialysis (Arem[0-1]), Arem (1-2), Arem (2-3), Arem (3-4) for Part 2

    Arem is defined as the total amount of drug removed using the hemodialysis method at different timepoints namely Arem (0-1), measured the amount of drug removed by hemodialysis from time 0 to 1 hour after the start of hemodialysis; Arem (1-2), measured the amount of drug removed by hemodialysis from time 1 to 2 hours after the start of hemodialysis; Arem(2-3) ), measured the amount of drug removed by hemodialysis from time 2 to 3 hour, Arem (3-4), measured the amount of drug removed by hemodialysis from hemodialysis from time 3 to 4 hours after the start of hemodialysis (or to the end of dialysis if \<4 hours). Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1Dialysate fluid were collected at 1, 2, 3, and 4 hours post-dose in Period 1 only

07

Results

Posted Nov 20, 2018

Participant flow

A 2-part study, conducted in participant's with varying degree of renal impairment (RI) which enrolled 32 participants, wherein, 24 participants were enrolled in Part 1 and 8 participants in Part 2. The study was conducted, at 3 centers in United States of America from 29 June 2016 to 20 June 2017.

Part 1 (Up to 44 Days)
Participant flow — Part 1 (Up to 44 Days)
MilestoneNormal, Part 1ModerateSevere/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis, Part 2
Started8880
Completed8880
Not completed0000
Part 2 (Up to 50 Days)
Participant flow — Part 2 (Up to 50 Days)
MilestoneNormal, Part 1ModerateSevere/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis, Part 2
Started0008
Completed0008
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1

AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity . Blood samples were collected at the indicated time-points, during the study. The Pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. The PK Population consisted of all participant's, who received at least 1 dose of gepotidacin and had evaluable PK data.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · Nanogram*hour per milliliter
Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1
Nanogram*hour per milliliterNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 114838 ± 20.722367 ± 17.028545 ± 21.4
Statistical analysis
  • Normal, Part 1 vs Moderate, Part 1 · Ratio of geometric ls means: 1.507 · 90% CI 0.902 to 2.519AUC (0-inf) for participants with normal renal function Vs participants with moderate renal function has been presented.
  • Normal, Part 1 vs Severe/ESRD Not on Hemodialysis, Part 1 · Ratio of geometric ls means: 1.924 · 90% CI 1.151 to 3.215AUC (0-inf) for participants with normal renal function Vs participants with Severe/ESRD not on hemodialysis
PrimaryAUC (0-inf) of Gepotidacin for Part 2

AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for gepotidacin. Blood samples were collected at the indicated time-points, during the study.

Time frame:
Pre-dose, 0.25 hours, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Geometric mean · Nanogram*hour per milliliter
AUC (0-inf) of Gepotidacin for Part 2
Nanogram*hour per milliliterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
AUC (0-inf) of Gepotidacin for Part 214838 ± 20.735239 ± 95.060461 ± 140.5
Statistical analysis
  • Normal, Part 1 vs ESRD on Hemodialysis (Before Hemodialysis), Part 2 · Ratio of geometric ls means: 2.375 · 90% CI 1.421 to 3.969AUC (0-inf) for participants with normal renal function Vs ESRD on hemodialysis (before hemodialysis)
  • Normal, Part 1 vs ESRD on Hemodialysis (After Hemodialysis), Part 2 · Ratio of geometric ls means: 4.075 · 90% CI 2.438 to 6.810AUC (0-inf) for participants with normal renal function Vs ESRD on hemodialysis (after hemodialysis)
PrimaryMaximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1

Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · nanogram per milliliter
Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1
nanogram per milliliterNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 14498 ± 16.35306 ± 16.07084 ± 23.3
Statistical analysis
  • Normal, Part 1 vs Moderate, Part 1 · Ratio of geometric ls means: 1.179 · 90% CI 0.467 to 2.977Cmax for participants with normal renal function Vs participants with moderate renal function has been presented.
  • Normal, Part 1 vs Severe/ESRD Not on Hemodialysis, Part 1 · Ratio of geometric ls means: 1.575 · 90% CI 0.624 to 3.975Cmax for participants with normal renal function Vs .participants with Severe/ESRD not on hemodialysis
PrimaryCmax of Gepotidacin for Part 2

Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both.
Reported as:
Geometric mean · nanogram per milliliter
Cmax of Gepotidacin for Part 2
nanogram per milliliterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Cmax of Gepotidacin for Part 24498 ± 16.310123 ± 216.326839 ± 797.1
Statistical analysis
  • Normal, Part 1 vs ESRD on Hemodialysis (Before Hemodialysis), Part 2 · Ratio of geometric ls means: 2.250 · 90% CI 0.891 to 5.681Cmax for participants with normal renal function Vs ESRD on hemodialysis (before hemodialysis)
  • Normal, Part 1 vs ESRD on Hemodialysis (After Hemodialysis), Part 2 · Ratio of geometric ls means: 5.966 · 90% CI 2.363 to 15.062Cmax for participants with normal renal function Vs ESRD on hemodialysis (after hemodialysis)
PrimaryTotal Amount Excreted in Urine (Ae Total), Part 1

Urine samples from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. No formal statistical analysis of group comparison was planned for urine PK parameters.

Time frame:
Pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
Reported as:
Geometric mean · milligram.
Total Amount Excreted in Urine (Ae Total), Part 1
milligram.Normal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Total Amount Excreted in Urine (Ae Total), Part 1280.49 ± 15.2165.86 ± 39.459.40 ± 68.3
PrimaryAe Total of Gepotidacin for Part 2

Urine samples, from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. Urine samples were collected at pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.

Time frame:
Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2
Reported as:
Geometric mean · milligram
Ae Total of Gepotidacin for Part 2
milligramNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Ae Total of Gepotidacin for Part 2280.49 ± 15.27.87 ± 96.410.87 ± 64.7
PrimaryPercentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1

The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100.

Time frame:
At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
Reported as:
Geometric mean · Percentage of gepotidacin
Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1
Percentage of gepotidacinNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 137.40 ± 15.222.11 ± 39.47.92 ± 68.3
Primaryfe% of Gepotidacin for Part 2

The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100. No formal statistical analysis of group comparison was planned for urine PK parameters. Only those participants available at the specified time points were analyzed.

Time frame:
At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods
Reported as:
Geometric mean · Percentage of gepotidacin
fe% of Gepotidacin for Part 2
Percentage of gepotidacinNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
fe% of Gepotidacin for Part 237.40 ± 15.21.05 ± 96.41.45 ± 64.7
PrimaryRenal Clearance (CLr) of Gepotidacin for Part 1

Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). The renal clearance was calculated by Ae total divided by AUC from hour 0 to the last measurable plasma concentration AUC (0-t). Urine samples were collected at pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. No formal statistical analysis of group comparison was planned for urine PK parameters.

Time frame:
At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
Reported as:
Geometric mean · Liter per hour
Renal Clearance (CLr) of Gepotidacin for Part 1
Liter per hourNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Renal Clearance (CLr) of Gepotidacin for Part 119.24 ± 18.87.58 ± 44.32.13 ± 84.3
PrimaryCLr of Gepotidacin for Part 2

Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). Urine samples were collected at pre-dose (0.0), 0 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.

Time frame:
At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods
Reported as:
Geometric mean · Liter per hour
CLr of Gepotidacin for Part 2
Liter per hourNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
CLr of Gepotidacin for Part 219.24 ± 18.80.29 ± 101.70.10 ± 277.5
PrimaryAUC (t0-t1) of Gepotidacin for Part 2

Partial area under the curve estimated from predialyzer samples collected from start of dialysis (t0) to end of dialysis (t1). Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm..

Time frame:
Dialysate fluid were to be collected on Day 1 after dosing (Period 1 only) at pre-dose from 0 to 4 hours
Reported as:
Geometric mean · Nanogram*hour per milliliter
AUC (t0-t1) of Gepotidacin for Part 2
Nanogram*hour per milliliterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
AUC (t0-t1) of Gepotidacin for Part 2—1062 ± 36.3—
PrimaryDialysis Clearance (CLD) of Gepotidacin for Part 2

CLD measured the dialysis clearance of gepotidacin over the specified duration in the study and indicates how quickly gepotidacin is cleared out from blood or plasma. Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm.

Time frame:
Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1
Reported as:
Geometric mean · Liter per hour
Dialysis Clearance (CLD) of Gepotidacin for Part 2
Liter per hourESRD on Hemodialysis (Before Hemodialysis), Part 2
Dialysis Clearance (CLD) of Gepotidacin for Part 26.63 ± 15.8
PrimaryFraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2

Dialysate samples were collected at specified time points in the study. Frem is defined as the fraction (dose in percentage) removed by the process of hemodialysis from 0 to 4 hours after the start of hemodialysis (or to the end of dialysis if less than 4 hours)

Time frame:
Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1
Reported as:
Geometric mean · Percentage of gepotidacin removed
Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2
Percentage of gepotidacin removedESRD on Hemodialysis (Before Hemodialysis), Part 2
Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 25.89 ± 26.2
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG) Readings for Part 1

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific timepoints during the study. No formal analysis of group comparison was planned for dialysate PK parameters

Time frame:
Up to 16 Days
Reported as:
Number · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Readings for Part 1
ParticipantsNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Baseline, Abnormal, NCS367
Baseline, Abnormal, CS000
Day 1 - 1.5 hour, Abnormal, NCS566
Day 1- 1.5 hour, Abnormal, CS000
Day 1- 2 hour, Abnormal, NCS366
Day 1- 2 hour, Abnormal, CS000
Day 1 - 4 hour, Abnormal, NCS267
Day 1- 4 hour, Abnormal CS000
Day 1 - 8 hour, Abnormal NCS266
Day 1 - 8 hour, Abnormal, CS000
Day 1 - 12 hour, Abnormal NCS267
Day 1 - 12 hour, Abnormal, CS000
Day 2 - 24 hour, Abnormal NCS375
Day 2 - 24 hour, Abnormal, CS000
Day 2 - 36 hour, Abnormal NCS266
Day 2 - 36 hour, Abnormal, CS000
Day 3 - 48 hour, Abnormal NCS265
Day3 - 48 hour, Abnormal, CS000
Follow-up, Abnormal NCS355
Follow-up, Abnormal CS000
SecondaryNumber of Participants With Abnormal 12-lead ECG Readings for Part 2

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific time points during the study. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). NA indicates data was not available

Time frame:
Up to 23 Days
Reported as:
Number · Participants
Number of Participants With Abnormal 12-lead ECG Readings for Part 2
ParticipantsESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Day 1- Baseline, Abnormal CS (n=8,8)00
Day 1 - Baseline, Abnormal NCS (n=8,8)67
Day 1- 2 hour, Abnormal, NCS (n=8,0)6—
Day 1- 2 hour, Abnormal, CS (n=8,0)0—
Day 1 - 4 hour, Abnormal, NCS (n=8,0)7—
Day 1- 4 hour, Abnormal CS (n=8,0)0—
Day 1 - 8 hour, Abnormal NCS (n=8,0)7—
Day 1 - 8 hour, Abnormal, CS (n=8,0)0—
Day 1 - 12 hour, Abnormal NCS (n=8,0)6—
Day 1 - 12 hour, Abnormal, CS (n=8,0)0—
Day 2 - 24 hour, Abnormal NCS (n=8,0)7—
Day 2 - 24 hour, Abnormal, CS (n=8,0)0—
Day 2 - 36 hour, Abnormal NCS (n=8,0)8—
Day 2 - 36 hour, Abnormal, CS (n=8,0)0—
Day 3 - 48 hour, Abnormal NCS (n=8,0)7—
Day3 - 48 hour, Abnormal, CS (n=8,0)0—
Day 8- 2 hour, Abnormal, NCS (n=0,8)—8
Day 8- 2 hour, Abnormal, CS (n=0,8)—0
Day 8 - 4 hour, Abnormal, NCS (n=0,8)—8
Day 8- 4 hour, Abnormal CS (n=0,8)—0
Day 8 - 8 hour, Abnormal NCS (n=0,8)—7
Day 8 - 8 hour, Abnormal, CS (n=0,8)—0
Day 8 - 12 hour, Abnormal NCS (n=0,8)—8
Day 8 - 12 hour, Abnormal, CS (n=0,8)—0
Day 9- 24 hour, Abnormal, NCS (n=0,8)—6
Day 9- 24 hour, Abnormal, CS (n=0,8)—0
Day 9 - 36 hour, Abnormal, NCS (n=0,8)—8
Day 9- 36 hour, Abnormal CS (n=0,8)—0
Day 10 - 48 hour, Abnormal NCS (n=0,8)—7
Day 10 - 48 hour, Abnormal, CS (n=0,8)—0
Follow-up, Abnormal NCS (n=0,8)—6
Follow-up, Abnormal CS (n=0,8)—0
SecondaryChange From Baseline in Vitals- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure, Part 1

Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Baseline was defined as the latest pre-dose assessment. Change from Baseline, was defined as post Baseline values minus the values at Baseline.

Time frame:
Baseline and up to 16 Days
Reported as:
Mean · Milliliter of mercury
Change From Baseline in Vitals- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure, Part 1
Milliliter of mercuryNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
SBP, Day 1- 1.5 hour,3.1 ± 2.366.8 ± 11.94-3.3 ± 13.77
SBP, Day 1- 2 hour,6.9 ± 12.548.3 ± 13.39-4.4 ± 12.73
SBP, Day 1 - 4 hour-0.9 ± 12.153.4 ± 5.421.0 ± 13.03
SBP, Day 1 - 8 hour,1.3 ± 12.695.9 ± 7.306.0 ± 12.75
SBP, Day 1 - 12 hour,-3.4 ± 12.2914.1 ± 12.894.6 ± 6.30
SBP, Day 2 - 24 hour,-1.1 ± 13.285.3 ± 6.65-4.1 ± 11.46
SBP, Day 2 - 36 hour0.5 ± 3.7414.4 ± 13.02-0.4 ± 9.12
SBP, Day 3 - 48 hour-1.0 ± 10.727.8 ± 9.10-6.0 ± 18.18
SBP, Follow-up0.8 ± 3.288.3 ± 13.06-4.8 ± 18.16
DBP, Day 1- 1.5 hour0.1 ± 3.91-1.3 ± 3.92-3.5 ± 7.19
DBP, Day 1- 2 hour,5.8 ± 7.151.3 ± 3.990.4 ± 4.07
DBP, Day 1 - 4 hour3.0 ± 5.50-2.4 ± 8.141.5 ± 4.99
DBP, Day 1 - 8 hour4.9 ± 6.06-4.3 ± 10.55-2.4 ± 6.95
DBP, Day 1 - 12 hour2.9 ± 6.36-0.5 ± 9.61-3.6 ± 4.66
DBP, Day 2 - 24 hour2.3 ± 5.501.0 ± 5.55-2.3 ± 4.17
DBP, Day 2 - 36 hour3.1 ± 8.22-0.8 ± 13.07-3.5 ± 3.96
DBP, Day 3 - 48 hour5.0 ± 7.690.6 ± 6.48-5.3 ± 5.87
DBP, Follow-up2.6 ± 5.480.5 ± 11.60-1.8 ± 6.58
SecondaryChange From Baseline in Vitals- SBP and DBP, Part 2

Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to 23 Days
Reported as:
Mean · Milliliter of mercury
Change From Baseline in Vitals- SBP and DBP, Part 2
Milliliter of mercuryESRD on Hemodialysis
SBP, Day 1- 2 hour, (n=8)-0.5 ± 14.91
SBP, Day 1 - 4 hour (n=8)8.6 ± 16.66
SBP, Day 1 - 8 hour, (n=8)-0.6 ± 23.93
SBP, Day 1 - 12 hour, (n=8)-4.8 ± 17.68
SBP, Day 2 - 24 hour, (n=8)1.4 ± 9.69
SBP, Day 2 - 36 hour (n=8)3.9 ± 10.33
SBP, Day 3 - 48 hour, (n=8)6.5 ± 5.53
SBP, Day 8-2 hour (n=8)-2.0 ± 8.16
SBP, Day 8-4 hour (n=8)-4.4 ± 7.46
SBP, Day 8-8 hour (n=8)-14.8 ± 14.50
SBP, Day 8-12 hour (n=6)-8.3 ± 7.92
SBP, Day 9-24 hour (n=8)5.9 ± 23.94
SBP, Day 9-36 hour (n=8)2.3 ± 20.11
SBP, Day 10-48 hour (n=8)12.6 ± 19.72
SBP, Follow-up, (n=8)0.5 ± 11.86
DBP, Day 1- 2 hour, (n=8)4.3 ± 11.31
DBP, Day 1 - 4 hour, (n=8)3.6 ± 9.83
DBP, Day 1 - 8 hour, (n=8)-1.5 ± 11.70
DBP, Day 1 - 12 hour (n=8)-2.3 ± 9.54
DBP, Day 2 - 24 hour (n=8)4.6 ± 9.68
DBP, Day 2 - 36 hour,(n=8)3.3 ± 6.11
DBP, Day 3 - 48 hour (n=7)3.0 ± 10.10
DBP, Day 8-2 hour, (n=8)-2.1 ± 10.49
DBP, Day 8-4 hour , (n=8)-2.5 ± 9.41
DBP, Day 8- 8 hour,(n=8)-6.9 ± 8.48
DBP, Day 8-12 hour, (n=8)-9.5 ± 10.03
DBP, Day 9-24 hour, (n=8)6.4 ± 9.41
DBP, Day 9-36 hour (n=8)2.6 ± 13.41
DBP, Day 10-48 hour (n=8)5.9 ± 11.74
DBP, Follow-up (n=8)2.3 ± 6.34
SecondaryChange From Baseline in Vitals- Pulse Rate, Part 1

Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment

Time frame:
Baseline and up to 16 Days
Reported as:
Mean · Beats per minute
Change From Baseline in Vitals- Pulse Rate, Part 1
Beats per minuteNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Pulse rate, Day 1- 1.5 hour0.1 ± 9.281.6 ± 4.213.5 ± 4.41
Pulse rate, Day 1- 2 hour1.8 ± 7.134.1 ± 3.234.1 ± 5.03
Pulse rate, Day 1 - 4 hour0.1 ± 6.490.4 ± 8.142.0 ± 5.63
Pulse rate, Day 1 - 8 hour-1.0 ± 13.401.8 ± 7.500.8 ± 4.46
Pulse rate, Day 1 - 12 hour-0.1 ± 12.313.4 ± 4.783.4 ± 1.92
Pulse rate, Day 2 - 24 hour1.0 ± 13.06-0.8 ± 7.85-2.3 ± 5.55
Pulse rate, Day 2 - 36 hour1.6 ± 9.56-0.5 ± 5.370.6 ± 5.24
Pulse rate, Day 3 - 48 hour-1.4 ± 10.76-0.1 ± 7.88-1.8 ± 7.34
Pulse rate, Follow-up-0.6 ± 10.340.6 ± 8.450.0 ± 7.43
SecondaryChange From Baseline in Vitals- Pulse Rate, Part 2

Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and Up to 23 Days
Reported as:
Mean · beats per minute
Change From Baseline in Vitals- Pulse Rate, Part 2
beats per minuteESRD on Hemodialysis
Pulse rate, Day 1- 2 hour, (n=8)0.4 ± 8.78
Pulse rate, Day 1 - 4 hour, (n=8)3.4 ± 9.09
Pulse rate, Day 1 - 8 hour, (n=8)4.4 ± 9.46
Pulse rate, Day 1 - 12 hour, (n=7)4.4 ± 10.21
Pulse rate, Day 2 - 24 hour, (n=8)2.5 ± 7.11
Pulse rate, Day 2 - 36 hour, (n=8)6.1 ± 9.96
Pulse rate, Day 3 - 48 hour, (n=7)3.6 ± 5.88
Pulse rate, Day, 8-2 hour (n=8)4.8 ± 10.38
Pulse rate, Day 8-4 hour (n=7)2.1 ± 5.08
Pulse rate, Day 8-8 hour ,(n=8)3.4 ± 7.69
Pulse rate, Day 8-12 hour (n=8)4.7 ± 10.05
Pulse rate, Day 9-24 hour (n=8)4.0 ± 11.51
Pulse rate, Day9-36 hour (n=8)8.9 ± 16.19
Pulse rate, Day 10-48 hour (n=8)3.6 ± 11.04
Pulse rate, Follow-up (n=8)3.8 ± 10.22
SecondaryNumber of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) for Part 1

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame:
Up to 16 Days
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) for Part 1
ParticipantsNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Any SAE000
Any AE034
SecondaryNumber of Participants With Any AEs and Any SAEs for Part 2

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame:
Up to 23 Days
Reported as:
Number · Participants
Number of Participants With Any AEs and Any SAEs for Part 2
ParticipantsESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Any SAE00
Any AE43
SecondaryNumber of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 1

The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.

Time frame:
Up to 17 Days
Reported as:
Number · Participants
Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 1
ParticipantsNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Serum or plasma creatinine, Grade 3 or higher005
Serum glucose, Grade 3 or higher001
SecondaryNumber of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 2

The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.

Time frame:
Up to 24 Days
Reported as:
Number · Participants
Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 2
ParticipantsESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Serum or plasma creatinine, Grade 3 or higher80
Serum glucose, Grade 3 or higher20
SecondaryNumber of Participants With Abnormal Physical Examination Results for Part 1

Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.

Time frame:
Up to 16 Days

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Physical Examination Results for Part 2

Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.

Time frame:
Up to 23 Days

No measurements were reported for this outcome.

SecondaryAUC (0-t) of Gepotidacin for Part 1

Blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · Nanogram*hour per milliliter
AUC (0-t) of Gepotidacin for Part 1
Nanogram*hour per milliliterNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
AUC (0-t) of Gepotidacin for Part 114582 ± 20.821883 ± 17.127886 ± 21.4
Statistical analysis
  • Normal, Part 1 vs Severe/ESRD Not on Hemodialysis, Part 1 · Ratio of geometric ls means: 1.501 · 90% CI 0.894 to 2.520Normal Vs Moderate
  • Normal, Part 1 vs Severe/ESRD Not on Hemodialysis, Part 1 · Ratio of geometric ls means: 1.912 · 90% CI 1.139 to 3.212Normal Vs Severe/ESRD not on hemodialysis
SecondaryAUC (0-t) of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Geometric mean · Nanogram*hour per milliliter
AUC (0-t) of Gepotidacin for Part 2
Nanogram*hour per milliliterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
AUC (0-t) of Gepotidacin for Part 214582 ± 20.834633 ± 95.859311 ± 143.3
Statistical analysis
  • Normal, Part 1 vs ESRD on Hemodialysis (Before Hemodialysis), Part 2 · Ratio of geometric ls means: 2.375 · 90% CI 1.414 to 3.989Normal Vs ESRD on hemodialysis (before hemodialysis)
  • Normal, Part 1 vs ESRD on Hemodialysis (After Hemodialysis), Part 2 · Ratio of geometric ls means: 4.068 · 90% CI 2.422 to 6.831Normal Vs ESRD on hemodialysis (after hemodialysis)
SecondarySystemic Clearance (CL) of Gepotidacin for Part 1

Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).

Time frame:
At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose during the single treatment period.
Reported as:
Geometric mean · Liter per hour
Systemic Clearance (CL) of Gepotidacin for Part 1
Liter per hourNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Systemic Clearance (CL) of Gepotidacin for Part 150.55 ± 20.733.53 ± 17.026.27 ± 21.4
SecondaryCL of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).

Time frame:
At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose in each of the two treatment periods
Reported as:
Geometric mean · Liter per hour
CL of Gepotidacin for Part 2
Liter per hourNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
CL of Gepotidacin for Part 250.55 ± 20.721.28 ± 95.012.40 ± 140.5
SecondaryTerminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1

Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · Per hour
Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1
Per hourNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 10.06027 ± 11.90.06369 ± 16.10.06266 ± 13.4
SecondaryLambda_z of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both
Reported as:
Geometric mean · Per hour
Lambda_z of Gepotidacin for Part 2
Per hourNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Lambda_z of Gepotidacin for Part 20.06027 ± 11.90.07338 ± 8.40.06428 ± 16.4
SecondaryTerminal Phase Half-life (t1/2) of Gepotidacin for Part 1

Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Median · hours
Terminal Phase Half-life (t1/2) of Gepotidacin for Part 1
hoursNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Terminal Phase Half-life (t1/2) of Gepotidacin for Part 111.663 (9.549 to 13.065)11.421 (7.402 to 12.259)11.246 (8.901 to 14.046)
Secondaryt1/2 of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Median · hours
t1/2 of Gepotidacin for Part 2
hoursNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
t1/2 of Gepotidacin for Part 211.663 (9.549 to 13.065)9.455 (8.441 to 10.915)11.121 (8.275 to 12.896)
SecondaryTime to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1

Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1
hoursNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part12.000 (1.00 to 2.00)2.000 (1.50 to 2.00)2.000 (0.25 to 2.50)
SecondaryTmax of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Median · hours
Tmax of Gepotidacin for Part 2
hoursNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Tmax of Gepotidacin for Part 22.000 (1.00 to 2.00)2.000 (0.50 to 2.02)1.575 (0.25 to 2.00)
SecondaryVolume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1

Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · Liter
Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1
LiterNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1255 ± 21.7223 ± 14.8181 ± 23.5
SecondaryVss of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Geometric mean · Liter
Vss of Gepotidacin for Part 2
LiterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Vss of Gepotidacin for Part 2255 ± 21.7114 ± 335.649 ± 938.8
SecondaryVolume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1

Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Reported as:
Geometric mean · Liter
Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1
LiterNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1839 ± 25.3527 ± 29.1419 ± 27.0
SecondaryVz of Gepotidacin for Part 2

Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.

Time frame:
Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Reported as:
Geometric mean · Liter
Vz of Gepotidacin for Part 2
LiterNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Vz of Gepotidacin for Part 2839 ± 25.3290 ± 90.8193 ± 161.3
SecondaryCumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Normal

Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function.

Time frame:
At Pre-dose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours
Reported as:
Geometric mean · milligram
Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Normal
milligramNormal, Part 1
Ae(0-2)135.53 ± 21.0
Ae (2-4)59.95 ± 56.7
Ae (4-6)19.90 ± 18.4
Ae (6-8)19.47 ± 70.5
Ae (8-12)9.11 ± 86.9
Ae(12-24)12.30 ± 55.3
Ae(24-36)5.38 ± 52.1
Ae(36-48)3.00 ± 42.8
SecondaryCumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Moderate and Severe

Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
at pre-dose (0.0), 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 36, and 36 to 48 hours post-dose during the single treatment period
Reported as:
Geometric mean · milligram
Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Moderate and Severe
milligramModerate, Part 1Severe/ESRD Not on Hemodialysis, Part 1
Ae (0-6) (n=8, 8)119.79 ± 50.039.54 ± 94.9
Ae (6-12) (n=8, 8)21.67 ± 30.78.26 ± 44.8
Ae (12-24) (n=8, 8)12.81 ± 40.84.42 ± 160.0
Ae(24-36 (n=8, 8)5.25 ± 25.42.89 ± 29.8
Ae(36-48) (n=8,7)2.66 ± 50.31.17 ± 71.0
SecondaryAe(t1-t2) of Gepotidacin for Part 2

Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function. NA indicates data is not available due to insufficient participants.Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2
Reported as:
Geometric mean · milligram
Ae(t1-t2) of Gepotidacin for Part 2
milligramNormal, Part 1ESRD on Hemodialysis (Before Hemodialysis), Part 2ESRD on Hemodialysis (After Hemodialysis), Part 2
Ae (0-8)(n=0,3,3)—5.56 ± 123.48.12 ± 73.8
Ae (8-12) (n=8,3,3)9.11 ± 86.90.72 ± 32.11.16 ± 31.5
Ae (12-24) (n=8,3, 3)12.30 ± 55.30.81 ± 147.51.31 ± 52.5
Ae (24-36) (n=8,2,1)5.38 ± 52.10.45 ± 154.40.75 ± NA
Ae (36-48) (n=8,2,0)3.00 ± 42.80.14 ± 133.2—
SecondaryTotal Amount of Unchanged Amount of Drug Removed by Hemodialysis (Arem) From Time 0 to 1 Hour After the Start of Hemodialysis (Arem[0-1]), Arem (1-2), Arem (2-3), Arem (3-4) for Part 2

Arem is defined as the total amount of drug removed using the hemodialysis method at different timepoints namely Arem (0-1), measured the amount of drug removed by hemodialysis from time 0 to 1 hour after the start of hemodialysis; Arem (1-2), measured the amount of drug removed by hemodialysis from time 1 to 2 hours after the start of hemodialysis; Arem(2-3) ), measured the amount of drug removed by hemodialysis from time 2 to 3 hour, Arem (3-4), measured the amount of drug removed by hemodialysis from hemodialysis from time 3 to 4 hours after the start of hemodialysis (or to the end of dialysis if \<4 hours). Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1Dialysate fluid were collected at 1, 2, 3, and 4 hours post-dose in Period 1 only
Reported as:
Geometric mean · milligram
Total Amount of Unchanged Amount of Drug Removed by Hemodialysis (Arem) From Time 0 to 1 Hour After the Start of Hemodialysis (Arem[0-1]), Arem (1-2), Arem (2-3), Arem (3-4) for Part 2
milligramESRD on Hemodialysis (Before Hemodialysis), Part 2
Arem (0-1), (n=8)18.22 ± 27.7
Arem (1-2), (n=8)12.42 ± 34.8
Arem (2-3), (n=8)8.93 ± 32.5
Arem (3-4), (n=6)5.35 ± 36.6

Adverse events

Collected over AEs and SAEs were collected from the start of study treatment upto 94 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal, Part 10/8 (0%)0/8 (0%)0/8 (0%)
Moderate, Part 10/8 (0%)0/8 (0%)4/8 (50%)
Severe/ESRD Not on Hemodialysis, Part 10/8 (0%)0/8 (0%)4/8 (50%)
ESRD on Hemodialysis (Before Hemodialysis)0/8 (0%)0/8 (0%)4/8 (50%)
ESRD on Hemodialysis (After Hemodialysis)0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventNormal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis (Before Hemodialysis)ESRD on Hemodialysis (After Hemodialysis)
DiarrhoeaGastrointestinal disorders0/81/82/84/80/8
Abdominal painGastrointestinal disorders0/82/82/80/80/8
FlatulenceGastrointestinal disorders0/80/80/82/80/8
Abdominal discomfortGastrointestinal disorders0/81/80/80/80/8
Faeces softGastrointestinal disorders0/81/80/80/80/8
NauseaGastrointestinal disorders0/80/81/80/80/8
Dizziness posturalNervous system disorders0/81/80/80/80/8
HeadacheNervous system disorders0/80/81/81/80/8
Infusion site erythemaGeneral disorders0/80/81/80/80/8
Musculoskeletal painMusculoskeletal and connective tissue disorders0/81/80/80/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Normal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis, Part 2Total
Mean61.5 ± 10.7872.0 ± 7.0561.4 ± 12.4951.8 ± 7.0961.6 ± 2.72
Sex: Female, Male
Sex: Female, Male(Participants)Normal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis, Part 2Total
Female31419
Male574723
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Normal, Part 1Moderate, Part 1Severe/ESRD Not on Hemodialysis, Part 1ESRD on Hemodialysis, Part 2Total
American Indian or Alaska Native01001
Black or African American112812
White: White/Caucasian/European765018
Multiple: African American/African/White00101
08

Study locations

3 sites
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Hossain M, Tiffany C, Raychaudhuri A, Nguyen D, Tai G, Alcorn H Jr, Preston RA, Marbury T, Dumont E. Pharmacokinetics of Gepotidacin in Renal Impairment. Clin Pharmacol Drug Dev. 2020 Jul;9(5):560-572. doi: 10.1002/cpdd.807. Epub 2020 May 19. PubMed 32429000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jun 2017, 11 months.

Results were first posted in Nov 2018, 1 year 5 months after primary completion.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 11 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 6, 2016
StartActual
Jun 29, 2016
Primary completionActual
Jun 20, 2017
CompletionActual
Jun 20, 2017
Results first posted
Nov 20, 2018
Last update
Jul 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02729038
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 6, 2016
Start date
Jun 29, 2016
Primary completion
Jun 20, 2017
Completion
Jun 20, 2017
Results posted
Nov 20, 2018
Last update
Jul 21, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion